20:47 , May 2, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Tumor mutations of 22 genes could help diagnose prostate cancer, and mutations in two of them could help predict patient outcomes. Whole-genome sequencing of 112 primary and metastatic prostate cancer and matched normal...
08:00 , Feb 26, 2015 |  BC Innovations  |  Targets & Mechanisms

A LRRKing safety problem

For reasons ranging from increased transparency to promoting reproducibility of preclinical research, many have called for a culture change in how journals, companies and academics view the publication of negative data. Genentech Inc. is setting...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

E6201: Development discontinued

Eisai disclosed in its 2Q13 earnings for the period ending Sept. 30 that it discontinued development of E6201. The product was in Phase II testing in the U.S. and EU to treat psoriasis. Eisai Co....
07:00 , Jul 12, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Genomic markers to guide the use of neoadjuvant aromatase inhibitors in patients with breast cancer Whole-genome and exome sequencing of...
08:00 , Dec 9, 2010 |  BC Innovations  |  Cover Story

Melanoma: three ways around BRAF inhibition

Independent research teams have identified three mechanisms by which melanoma can develop resistance to BRAF inhibitors,1,2 a promising class of therapeutics that include late-stage clinical compounds from Plexxikon Inc. and GlaxoSmithKline plc. The findings suggest...
07:00 , Jun 10, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer; gastric cancer; melanoma BRAF; CRAF (RAF1); MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2) Genomic...
07:00 , May 31, 2010 |  BC Week In Review  |  Clinical News

E6201: Phase I data

In an open-label, dose-escalating Phase I trial in 25 patients with advanced solid tumors, E6201 led to 1 case of stable disease for >10 months in a patient with metastatic ocular melanoma and 1 partial...
07:00 , May 13, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Gastrointestinal disease Adenomatous polyps MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2); myeloid differentiation primary response gene 88...
08:00 , Nov 13, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...
07:00 , Mar 31, 2008 |  BioCentury  |  Regulation

EGFR pathway

EGFR pathway Vectibix panitumumab and other epidermal growth factor (EGF) receptor inhibitors are intended to prevent the growth and survival of cells that express EGFR. However, the Ras pathway is downstream of EGFR, so if a...